Inspra Tablet, Film Coated
Product Images NDC 58151-142

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Inspra (NDC 58151-142). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Viatris Specialty Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula Of Eplerenone (Image 01)

Chemical structure of eplerenone, the active ingredient in Inspra. The diagram shows the molecular arrangement of the steroidal compound with characteristic rings and functional groups as depicted in the image.*

FDA Label Image

Figure 1 (Image 02)

A cumulative incidence plot comparing the outcomes over approximately 27 months between Placebo and Inspra (eplerenone) groups. The x-axis represents months since randomization, and the y-axis shows cumulative incidence percentage. The graph indicates lower incidence in the Inspra group compared to placebo, with risk numbers at various time points and a statistical significance value (p=0.008) noted.*

FDA Label Image

Figure 3 (Image 03)

A scatter plot graph showing the reduction in systolic blood pressure (SBP) in mmHg on the vertical axis against doses of Inspra (eplerenone) in mg/day on the horizontal axis. Data points represent three study groups with different dosing regimens: Study 1 QD, Study 2 QD, and Study 2 BID, illustrating the relationship between Inspra dosage and SBP reduction.*

FDA Label Image

Figure 4 (Image 04)

A scatter plot chart showing the reduction in diastolic blood pressure (DBP) in mm Hg versus the Inspra dose in mg/day. Data points represent results from two studies with different dosing schedules: Study 1 QD, Study 2 QD, and Study 2 BID, indicating the effect of Inspra on DBP reduction at various doses up to 200 mg/day.*

FDA Label Image

Figure 2 (Image 05)

A forest plot chart illustrating overall mortality hazard ratios with 95% confidence intervals across subgroups for patients treated with eplerenone versus placebo. The subgroups include age, gender, race, diabetes status, hypertension status, Killip class, creatinine clearance, and baseline use of beta blockers, ACE inhibitors, digoxin, and diuretics. The chart shows number of events and patients for each subgroup with a hazard ratio scale from 0 to 2.*

FDA Label Image

Ndc 58151-142-93 (Image 06)

Label for Inspra 25 mg (eplerenone) tablets, oral film-coated tablets, supplied in a bottle of 30 tablets. The label shows the dosage strength, quantity, Rx only designation, and distributor as Viatris Specialty LLC. Storage information includes storing at 25°C with permitted excursions between 15-30°C.*

FDA Label Image

Ndc 58151-143-93 (Image 07)

Label for Inspra (eplerenone) tablets, 50 mg strength, film-coated oral tablets. The package contains 30 tablets and is labeled for prescription use only. Distributed by Viatris Specialty LLC, Morgantown, WV. Storage instructions and other regulatory details are included on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.